APHON Pediatric Chemotherapy-Biotherapy Renewal

Narayanan, K. R., Bansal, D., Walia, R., Sachdeva, N., Bhansali, A., Varma, N., & Marwaha, R. K. (2013). Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis. Pediatric Blood and Cancer , 60 (7),1148–1153. https://doi.org/10.1002/pbc.24397 National Center for Biotechnology Information. (2021). PubChem Compound Summary for CID 6918289, Temsirolimus. Retrieved September 15, 2021, from https://pubchem.ncbi.nlm.nih.gov/compound/temsirolimus National Comprehensive Cancer Network. (2021). NCCN Clinical Practice Guidelines in Oncology. Antiemesis, Version 1.2021. www.nccn.org National Institute for Occupational Safety and Health. (2016). NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2016 (DHHS NIOSH Publication Number 2016- 161). Retrieved September 15, 2021, from https://www.cdc.gov/niosh/docs/2016- 161/default.html National Institute for Occupational Safety and Health. [2020]. NIOSH list of hazardous drugs in healthcare settings, 2020 [Draft]. By Connor, T. H., MacKenzie, B. A., DeBord, D. G., Trout, D. B., O’Callaghan, J. P., Ovesen, J. L., & Whittaker, C. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication Number 2020-xxx (Supersedes 2016-161). https://www.cdc.gov/niosh/docket/review/docket233c/pdfs/DRAFT-NIOSH-Hazardous-Drugs- List-2020.pdf Novartis. (2020). Tafinlar: Highlights of prescribing information. https://www.novartis.us/sites/www.novartis.us/files/tafinlar.pdf Ricart, A. D. (2017). Drug-induced liver injury in oncology. Annals of Oncology , 28 (8), 2013–2020. https://doi.org/10.1093/annonc/mdx158 Secombe, K. R., Van Sebille, Y. Z. A., Mayo, B. J., Coller, J. K., Gibson, R. J., & Bowen, J. M. (2020). Diarrhea induced by small molecule tyrosine kinase inhibitors compared with chemotherapy: Potential role of the microbiome. Integrative Cancer Therapies , 19, 1–12. https://doi.org/10.1177/1534735420928493 U.S. Pharmacopeial Convention. (2016). General chapter <800>: Hazardous drugs–Handling in healthcare settings . http://www.usp.org Westover, D., Zugazagoitia, J., Cho, B. C., Lovly, C. M., & Paz-Ares, L. (2018). Mechanisms of acuired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Annals of Oncology , 29 (suppl 1), i10–i19. https://doi.org/10.1093/annonc/mdx703